NASDAQ · TRAX
First Tracks Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TRAX: Nov 11, 2026
First Tracks Biotherapeutics, Inc. Ordinary Shares is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.92.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.92 | $-0.80 | $-0.97 | 4 |
| Dec 2026 | $-0.92 | $-0.78 | $-1.00 | 4 |
| Mar 2027 | $-0.92 | $-0.80 | $-1.05 | 3 |
| Jun 2027 | $-0.94 | $-0.77 | $-1.13 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Barchart · MarketBeat · RTTNews · Fintel- Barchart · Oct 13, 2:37 PM EDTStocks Settle Lower as Crude Prices Jump and Chipmakers FallThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.06% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.71%. December E-mini S&P futures (ESZ26 ) fell -0.04%, and December E-mini…
- Barchart · Oct 12, 7:21 PM EDTStocks Mixed Ahead of Q3 Earnings SeasonThe S&P 500 Index ($SPX ) (SPY ) is up by +0.09% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.35%. December E-mini S&P futures (ESZ26 ) are up +0.07%, and December E-mini…
- Barchart · Oct 12, 7:15 PM EDTStocks Pressured by Rising Crude Prices and Chipmaker WeaknessThe S&P 500 Index ($SPX ) (SPY ) is down by -0.07% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.69%. December E-mini S&P futures (ESZ26 ) are down -0.05%, and December E-mini…
- MarketBeat · Oct 12, 1:02 PM EDTFirst Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study GoalsFirst Tracks Biotherapeutics (NASDAQ:TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge. T
- RTTNews · Oct 12, 3:54 AM EDTFirst Track To Report Top-Line Phase 1b ANB033 Data In Celiac Disease Today; Stock Up(RTTNews) – First Tracks Biotherapeutics, Inc. (TRAX), a clinical-stage biotechnology company, is set to review top-line data from the Cohort 1 Phase 1b trial of ANB033 in celiac disease during an investor webcast on October 12, 2026.
- Fintel · Sep 30, 10:07 AM EDTCanaccord Genuity initiates coverage of First Tracks Biotherapeutics with a Buy ratingFintel reports that on September 30, 2026, Canaccord Genuity initiated coverage of First Tracks Biotherapeutics (NASDAQGS:TRAX) (BMV:TRAX) with a Buy recommendation.Prior to this rating action, the stock recorded a pre_action_close of $35.98 on September 29, 2026, which is also t
- Fintel · Sep 16, 2:59 PM EDTGuggenheim Initiates Coverage of First Tracks Biotherapeutics with BuyFintel reports that on September 16, 2026, Guggenheim initiated coverage of First Tracks Biotherapeutics (NASDAQGS:TRAX) with a Buy recommendation. Prior to this rating action, the stock closed at $38.47 on September 15, 2026. This pre-action close of $38.47 represents a one-week
- RTTNews · Jul 31, 6:57 AM EDTBiotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR(RTTNews) – The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements.
- RTTNews · Jul 27, 11:29 PM EDTTop Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired(RTTNews) – Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debu
- RTTNews · Jul 10, 8:17 AM EDTBiotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT(RTTNews) – The following biotech companies climbed to 52-week highs on July 9, 2026, driven by key catalysts like encouraging regulatory updates and clinical trial milestones.
- RTTNews · Jul 9, 10:50 PM EDTTop Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch(RTTNews) – Today's top biotech gainers include Virax Biolabs, following its agreement with Fosun Diagnostics; Forte Biosciences, after reporting positive vitiligo data; Connect Biopharma, with a key near-term catalyst ahead; and SANUWAVE Health, despite recently lowering its sec
- RTTNews · Jun 30, 10:40 PM EDTTop Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus(RTTNews) – Today's top gainers in the biotech space include Cuprina, which recently received FDA clearance for its maggot-based wound treatment; ABIVAX, following encouraging results from an ulcerative colitis study; ProMIS, which has a key catalyst to watch this quarter; and su
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for First Tracks Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.